Getinge (OTCMKTS:GNGBY) Downgraded by Zacks Research to Hold

Getinge (OTCMKTS:GNGBY – Get Free Report) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks reports.

A number of other research firms also recently weighed in on GNGBY. UBS Group initiated coverage on shares of Getinge in a research report on Wednesday, September 2nd. They issued a “hold” rating on the stock. Nordea Equity Research cut shares of Getinge from a “buy” rating to a “hold” rating in a research report on Monday, August 31st. Three analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company has an average rating of “Hold”.

Get Getinge alerts:

Read Our Latest Stock Analysis on GNGBY

Getinge Trading Down 1.3%

OTCMKTS GNGBY opened at $23.93 on Thursday. The firm has a market capitalization of $6.52 billion, a PE ratio of 22.79 and a beta of 0.93. The stock’s 50 day moving average is $24.58 and its 200 day moving average is $21.93. Getinge has a twelve month low of $18.99 and a twelve month high of $25.98. The company has a quick ratio of 0.74, a current ratio of 1.31 and a debt-to-equity ratio of 0.26.

Getinge (OTCMKTS:GNGBY – Get Free Report) last posted its quarterly earnings data on Friday, July 17th. The company reported $0.38 earnings per share (EPS) for the quarter. The business had revenue of $894.87 million during the quarter. Getinge had a return on equity of 11.12% and a net margin of 7.81%. Research analysts forecast that Getinge will post 1.38 earnings per share for the current fiscal year.

About Getinge

(Get Free Report)

Getinge AB is a Sweden-based medical technology company that develops products and solutions for hospitals, healthcare providers and life science organizations. Founded in 1904 in Getinge, Sweden, the company serves customers through operations and sales channels across Europe, North America, Asia-Pacific and other international markets.

Getinge organizes its business around Acute Care Therapies, Life Science and Surgical Workflows. Its offerings include ventilators, anesthesia systems, patient monitoring and cardiovascular support technologies, as well as equipment used in intensive care and other acute-care settings.

Read More

• Five stocks we like better than Getinge
• J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
• 2 Stocks Breaking Out Post-FOMC With One Thing in Common
• Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
• These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons

Receive News & Ratings for Getinge Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Getinge and related companies with MarketBeat.com's FREE daily email newsletter.